Voloridge Investment Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,165,043
| Closed | -$73.2M | – | 1248 |
|
|
2024
Q4 | $73.2M | Buy |
2,165,043
+2,016,795
| +1,360% | +$72.6M | 0.26% | 111 |
|
|
2024
Q3 | $6.06M | Buy |
+148,248
| New | +$6.06M | 0.02% | 732 |
|
|
2023
Q4 | – | Sell |
-433,067
| Closed | -$15.7M | – | 1282 |
|
|
2023
Q3 | $15.7M | Sell |
433,067
-83,510
| -16% | -$2.96M | 0.08% | 341 |
|
|
2023
Q2 | $18.4M | Sell |
516,577
-385,119
| -43% | -$13.8M | 0.09% | 308 |
|
|
2023
Q1 | $32.1M | Buy |
901,696
+724,075
| +408% | +$25.3M | 0.16% | 191 |
|
|
2022
Q4 | $6.24M | Sell |
177,621
-366,584
| -67% | -$12.2M | 0.03% | 575 |
|
|
2022
Q3 | $16M | Sell |
544,205
-394,761
| -42% | -$15M | 0.09% | 315 |
|
|
2022
Q2 | $51.1M | Buy |
938,966
+754,200
| +408% | +$41.6M | 0.26% | 101 |
|
|
2022
Q1 | $10.1M | Buy |
184,766
+21,174
| +13% | +$1.15M | 0.06% | 403 |
|
|
2021
Q4 | $9.02M | Buy |
+163,592
| New | +$8.51M | 0.05% | 500 |
|
|
2021
Q2 | – | Sell |
-543,186
| Closed | -$24.2M | – | 1675 |
|
|
2021
Q1 | $24.2M | Sell |
543,186
-214,778
| -28% | -$9.75M | 0.18% | 148 |
|
|
2020
Q4 | $34.9M | Sell |
757,964
-86,871
| -10% | -$3.99M | 0.29% | 72 |
|
|
2020
Q3 | $39.7M | Buy |
844,835
+304,457
| +56% | +$15.3M | 0.33% | 68 |
|
|
2020
Q2 | $27.6M | Buy |
540,378
+275,956
| +104% | +$14.2M | 0.32% | 60 |
|
|
2020
Q1 | $12.5M | Sell |
264,422
-160,982
| -38% | -$8.59M | 0.36% | 56 |
|
|
2019
Q4 | $25M | Buy |
425,404
+290
| +0.1% | +$16.1K | 0.49% | 28 |
|
|
2019
Q3 | $22.7M | Buy |
425,114
+237,196
| +126% | +$12.2M | 0.39% | 32 |
|
|
2019
Q2 | $9.4M | Buy |
187,918
+153,464
| +445% | +$7.7M | 0.26% | 83 |
|
|
2019
Q1 | $1.8M | Buy |
+34,454
| New | +$1.72M | 0.05% | 318 |
|
|
2018
Q1 | – | Sell |
-273,831
| Closed | -$12.1M | – | 550 |
|
|
2017
Q4 | $12.1M | Buy |
+273,831
| New | +$12.6M | 0.26% | 93 |
|
|
2017
Q3 | – | Sell |
-66,452
| Closed | -$3.58M | – | 437 |
|
|
2017
Q2 | $3.58M | Buy |
+66,452
| New | +$3.54M | 0.09% | 219 |
|
|
2017
Q1 | – | Sell |
-344,218
| Closed | -$16.6M | – | 559 |
|
|
2016
Q4 | $16.6M | Buy |
+344,218
| New | +$17M | 0.36% | 67 |
|
|
2016
Q2 | – | Sell |
-287,182
| Closed | -$14.6M | – | 347 |
|
|
2016
Q1 | $14.6M | Buy |
+287,182
| New | +$14.3M | 0.34% | 68 |
|
|
2015
Q4 | – | Sell |
-106,167
| Closed | -$5.1M | – | 233 |
|
|
2015
Q3 | $5.1M | Buy |
+106,167
| New | +$5.53M | 0.24% | 108 |
|
Other funds holding GSK
JEST
Voloridge Investment Management's GSK Position: Q1 2025 in Review
Voloridge Investment Management sold out of GSK (GSK) in Q1 2025, closing a stake of 2,165,043 shares — an estimated $73.2M sold.
Voloridge Investment Management first reported a position in GSK in Q3 2015 and held it in 24 quarters. The position peaked at $73.2M in Q4 2024. 858 funds tracked by Wall St. Rank hold GSK as of Q1 2025.
- Voloridge Investment Management reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
- Voloridge Investment Management sold 2,165,043 GSK shares in Q1 2025, an estimated $73.2M.
- Voloridge Investment Management first reported a position in GSK in Q3 2015 and held it in 24 quarters.
- Voloridge Investment Management's GSK position peaked at $73.2M in Q4 2024.
- 858 funds tracked by Wall St. Rank held GSK as of Q1 2025.
Based on Voloridge Investment Management's 13F filing for Q1 2025, filed 15 May 2025.